Canadian journal of anaesthesia = Journal canadien d'anesthésie
-
Comparative Study
Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery.
Recombinant factor VIIa (rFVIIa) is being used for refractory, excessive blood loss (EBL) after cardiac surgery, but its safety for this indication is not known. ⋯ In cardiac surgical patients with refractory hemorrhage, rFVIIa therapy is not associated with increased risk of AEs, and early treatment may be associated with better outcomes.